Moleculin's Annamycin Shows No Cardiotoxicity at High Doses, Presented at ASCO 2026
MBRX sits 54% above its 52-week low of $1.79.
Summary
Moleculin Biotech presented positive data at ASCO 2026 for its lead drug candidate, Annamycin, demonstrating no detectable cardiotoxicity in a pooled analysis across five clinical trials. This finding, independently reviewed by Cleveland Clinic, is significant as Annamycin was administered at exposure levels far exceeding conventional anthracycline limits, which are typically constrained by severe cardiac side effects. This positive clinical development is crucial for Moleculin, which has recently issued 'going concern' warnings and requires substantial new capital. The company is advancing its pivotal Phase 2b/3 MIRACLE trial for relapsed/refractory AML, with unblinding of interim data for the first 45 patients expected in June 2026.
At the time of this announcement, MBRX was trading at $2.75 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $14.6M. The 52-week trading range was $1.79 to $24.00. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.